Condition: Kidney Transplant · Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
This is a pediatric kidney transplant study comparing the safety and efficacy of an immunosuppressive regimen of belatacept and sirolimus to tacrolimus and Mycophenolate Mofetil (MMF). Two hundred participants will be randomized (1:1) to one of two groups within 24 hours following the transplant procedure. The duration of the study from time of transplant to the primary endpoint is 12-24 months.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham (Site # 71038) | Birmingham, Alabama, United States | Recruiting |
| Children's Hospital of Los Angeles (Site #: 71036) | Los Angeles, California, United States | Not Yet Recruiting |
| Cedars-Sinai Medical Center (Site #: 71026) | Los Angeles, California, United States | Recruiting |
| Mattel Children's Hospital, UCLA (Site #: 71012) | Los Angeles, California, United States | Recruiting |
| UCSD Rady Children's Hospital (Site #: 71037) | San Diego, California, United States | Recruiting |
| Children's Hospital of Colorado (Site #: 71019) | Aurora, Colorado, United States | Recruiting |
| Nemours Children's Health (Site #: 71042) | Wilmington, Delaware, United States | Recruiting |
| Children's National Medical Center (Site #: 71039) | Washington D.C., District of Columbia, United States | Recruiting |
| Ann and Robert H. Lurie Children's Hospital of Chicago (Site #: 71016) | Chicago, Illinois, United States | Recruiting |
| Johns Hopkins Children's Center (Site #: 71025) | Baltimore, Maryland, United States | Recruiting |
| Boston Children's Hospital (Site #: 71001) | Boston, Massachusetts, United States | Recruiting |
| Helen DeVos Children's Hospital (Site #: 71035) | Grand Rapids, Michigan, United States | Recruiting |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06055608